3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Unknown
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Neoplasms
4
Venous Thrombosis
2
Venous Thromboembolism
2
Colonic Neoplasms
2
Carcinoma, Hepatocellular
2
Thrombosis
1
Thromboembolism
1
Stomach Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Multiple Myeloma
1
Lung Neoplasms
1
Inflammation
1
Immune System Diseases
1
Glioma
1
Gastrointestinal Stromal Tumors
1
Gallbladder Neoplasms
1
Esophageal Neoplasms
1
Dyskinesias
1
Duodenal Neoplasms
1
Cholangiocarcinoma
1
Cardiovascular Diseases
1
Breast Neoplasms
1
Biliary Tract Neoplasms
1
Interventions
Cisplatin
38
Carboplatin
28
Gemcitabine
23
Docetaxel
20
Radiotherapy
18
Etoposide
15
Paclitaxel
13
Erlotinib Hydrochloride
13
Vinorelbine
11
Drug Therapy
11
pembrolizumab
9
aumolertinib
9
apatinib
9
Pemetrexed
9
Gefitinib
9
osimertinib
7
endostar protein
7
Thoracic Surgery, Video-Assisted
7
Blood Specimen Collection
7
camrelizumab
6
anlotinib
6
Vinblastine
6
Surgical Procedures, Operative
6
sintilimab
5
Radiosurgery
5
Fluorodeoxyglucose F18
5
Cyclophosphamide
5
Bevacizumab
5
durvalumab
4
Mitomycin
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Lung Neoplasms
×
Rivaroxaban
×
Clear all
NCT06065592
2023-10-06
CAT_PB
Lebanese University
Phase 1
Unknown
500 enrolled